部份中文ColyMycin M处方资料（仅供参考）
商品名：ColyMycin M
英文名: Colistimethate Sodium Injection
中文名: 多粘菌素注射剂
生产商: JHP PHARMACEUTICALS LLC
药品介绍
多粘菌素E甲磺酸钠 Colistimethate Sodium
中文别名：多粘菌素E甲磺酸钠、肠粘菌素甲磺酸钠、甲磺酸粘菌素、粘菌素甲磺酸钠、粘菌素甲烷磺酸钠
英文别名：Colimicina、Colimycine、Colistimethate、Colistimethatum Natricum、Colistin Sodium Methamesulfonate、Colistin Sulphomethate Sodium、Colistinm、Colistinmethane Sulfonate Sodium、Coly-Mycin、Coly-Mycin M、Methacolimycin、Pentasodium Colitinmethanesulfate
药品类别：其它抗生素类抗感染药
适应症
本品为绿脓杆菌感染的首选药物之一，可治绿脓杆菌性脑膜炎，也可用于败血症、泌尿系统、腹部及其它手术后感染。
用法用量
肌注或皮注：每次100万单位，1日2～4次。或遵医嘱！
注意事项
主要为肾毒性及神经毒性，但比硫酸多粘菌素Ｅ小。有时会出现暂时性的感觉异常、皮肤瘙痒、视觉障碍、语言紊乱、药物热、胃肠道菌群失调等。肾功能不全者慎用。
包装
COLY-MYCIN S OTIC DRP 10ML NEOMYC/COLIST/HYDROCORT/THONZN  ENDO LABORATORIES 63481042105
COLY-MYCIN M 150 MG VL 6X10ML COLISTIN (COLISTIMETHATE NA) JHP PHARMACEUTICALS LLC 42023010706
---------------------------------------------------------------
Coly-Mycin® M Parenteral (Colistimethate for Injection, USP)
Description
Coly-Mycin® M Parenteral (Colistimethate for Injection, USP) is a sterile parenteral antibiotic product which, when reconstituted (see Reconstitution ), is suitable for intramuscular or intravenous administration.
Each vial contains colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity).
Colistimethate sodium is a polypeptide antibiotic with an approximate molecular weight of 1750. The empirical formula is C58H105N16Na5O28S5 and the structural formula is represented below:
coly mycin m 1.jpg
Clinical Pharmacology
Typical serum and urine levels following a single 150 mg dose of Coly-Mycin M Parenteral IM or IV in normal adult subjects are shown in Figure 1.
coly mycin m 2.jpg
Higher serum levels were obtained at 10 minutes following IV administration. Serum concentration declined with a half-life of 2–3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants.
Average urine levels ranged from about 270 mcg/mL at 2 hours to about 15 mcg/mL at 8 hours after intravenous administration and from 200 to about 25 mcg/mL during a similar period following intramuscular administration.
Microbiology:
Colistimethate sodium is a surface active agent which penetrates into and disrupts the bacterial cell membrane. It has been shown to have bactericidal activity against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section:
Aerobic gram-negative microorganisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Susceptibility Testing: For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
REPORT PROBLEMS TO THE FOOD AND DRUG ADMINISTRATION
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.